Atenolol: Difference between revisions
imported>Robert Badgett |
imported>Robert Badgett m (→Dosage: Added doi) |
||
| Line 36: | Line 36: | ||
==Dosage== | ==Dosage== | ||
For healthy adults, the starting dose recommended by the manufacturer is 50 mg orally once daily and the maximum dose is 100 mg orally once daily. ''However'', atenolol may require twice daily dosing<ref name="pmid18259123">{{cite journal |author=Sarafidis P, Bogojevic Z, Basta E, Kirstner E, Bakris GL |title=Comparative efficacy of two different beta-blockers on 24-hour blood pressure control |journal=J Clin Hypertens (Greenwich) |volume=10 |issue=2 |pages=112–8 |year=2008 |month=February |pmid=18259123 |doi= |url= |issn=}}</ref> | For healthy adults, the starting dose recommended by the manufacturer is 50 mg orally once daily and the maximum dose is 100 mg orally once daily. ''However'', atenolol may require twice daily dosing<ref name="pmid18259123">{{cite journal |author=Sarafidis P, Bogojevic Z, Basta E, Kirstner E, Bakris GL |title=Comparative efficacy of two different beta-blockers on 24-hour blood pressure control |journal=J Clin Hypertens (Greenwich) |volume=10 |issue=2 |pages=112–8 |year=2008 |month=February |pmid=18259123 |doi=10.1111/j.1751-7176.2008.08021.x |url= |issn=}}</ref> | ||
==Efficacy== | ==Efficacy== | ||
Revision as of 07:56, 22 June 2009
|
| |||||||
| atenolol | |||||||
| |||||||
| Uses: | hypertention;angina pectoris | ||||||
| Properties: | hydrophilic | ||||||
| Hazards: | see side effects & drug interactions | ||||||
| |||||||
In medicine, atenolol is a cardioselective adrenergic beta-antagonist that is "possessing properties and potency similar to propranolol, but without a negative inotropic effect."[1] Atenolol is hydrophilic[2]
History
Atenolol was developed by the Stuart Company which was a division of Imperial Chemical Industries (ICI). ICI was renamed Zeneca in 1992. Atenolol received approval in the United States August 19, 1981.[3] According to drugstore.com, 90 days of generic 50 mg pills costs $17.99 in January, 2009.
Generic atenolol was available in 1988.[4]
Chemistry
Atenolol may defined by IUPAC nomenclature:
- 4-[2'-hydroxy-3'-[(1-methylethyl)amino]propoxy-benzeneacetamide
- Benzeneacetamide, 4-[2'-hydroxy-3'-[(1-methylethyl) amino] propoxy]- (according to [1])
It is a hydrophilic drug, with solubility in water equal to 26.5 mg/mL at 37ºC, with chemical formula C14H22N2O3 andmolecular mass 266.34 gram/mole for the free base form. It is freely soluble in strongly acidic solutions.
Metabolism
Atenolol is excreted unchanged in the kidneys. Elimination is dependent on the glomerular filtration rate. With normal renal function, the serum half-life is about 8 hours. While this means atenolol may need twice a day dosing for some diseases in which control of heart rate is important, atenolol can be used once a day for isolated hypertension because the central nervous system pharmacodynamic effect persists longer.
Atenolol is not metabolized in the liver by cytochrome P-450 2D6 allele.
Dosage
For healthy adults, the starting dose recommended by the manufacturer is 50 mg orally once daily and the maximum dose is 100 mg orally once daily. However, atenolol may require twice daily dosing[5]
Efficacy
Coronary heart disease
Heart failure
Although atenolol has not received indication in the United States for the treatment of heart failure, two cohort studies suggest that the beta-blockers atenolol and carvedilol may be more effect than metoprolol for the treatment of heart failure.[6][7]
Randomized controlled trials by one research group also suggest atenolol might benefit.[8][9]
Hypertension
Atenolol may not reduce mortality as well as other antihypertensives according to a systematic review; however, this review did not compare atenolol against other adrenergic beta-antagonists and it is not clear whether all of the included trials allowed patients with active coronary heart disease who would have most benefitted from a adrenergic beta-antagonist.[10]
External links
The most up-to-date information about Atenolol and other drugs can be found at the following sites.
- Atenolol - FDA approved drug information (drug label) from DailyMed (U.S. National Library of Medicine).
- Atenolol - Drug information for consumers from MedlinePlus (U.S. National Library of Medicine).
- Atenolol - Detailed information from DrugBank.
References
- ↑ Anonymous (2024), Atenolol (English). Medical Subject Headings. U.S. National Library of Medicine.
- ↑ Tuininga YS, Crijns HJ, Brouwer J, et al (December 1995). "Evaluation of importance of central effects of atenolol and metoprolol measured by heart rate variability during mental performance tasks, physical exercise, and daily life in stable postinfarct patients". Circulation 92 (12): 3415–23. PMID 8521562. [e]
- ↑ Drugs@FDA. U S Food and Drug Administration
- ↑ Drugs@FDA. U S Food and Drug Administration
- ↑ Sarafidis P, Bogojevic Z, Basta E, Kirstner E, Bakris GL (February 2008). "Comparative efficacy of two different beta-blockers on 24-hour blood pressure control". J Clin Hypertens (Greenwich) 10 (2): 112–8. DOI:10.1111/j.1751-7176.2008.08021.x. PMID 18259123. Research Blogging.
- ↑ Kramer JM, Curtis LH, Dupree CS, et al (December 2008). "Comparative effectiveness of beta-blockers in elderly patients with heart failure". Arch. Intern. Med. 168 (22): 2422–8; discussion 2428–32. DOI:10.1001/archinternmed.2008.511. PMID 19064824. Research Blogging.
- ↑ Go AS, Yang J, Gurwitz JH, Hsu J, Lane K, Platt R (December 2008). "Comparative effectiveness of different beta-adrenergic antagonists on mortality among adults with heart failure in clinical practice". Arch. Intern. Med. 168 (22): 2415–21. DOI:10.1001/archinternmed.2008.506. PMID 19064823. Research Blogging.
- ↑ Sturm B, Pacher R, Strametz-Juranek J, Berger R, Frey B, Stanek B (December 2000). "Effect of beta 1 blockade with atenolol on progression of heart failure in patients pretreated with high-dose enalapril". Eur. J. Heart Fail. 2 (4): 407–12. PMID 11113718. [e]
- ↑ Hülsmann M, Sturm B, Pacher R, et al (November 2001). "Long-term effect of atenolol on ejection fraction, symptoms, and exercise variables in patients with advanced left ventricular dysfunction". J. Heart Lung Transplant. 20 (11): 1174–80. PMID 11704477. [e]
- ↑ Carlberg B, Samuelsson O, Lindholm LH (2004). "Atenolol in hypertension: is it a wise choice?". Lancet 364 (9446): 1684–9. DOI:10.1016/S0140-6736(04)17355-8. PMID 15530629. Research Blogging.